The role of the Contract Development and Manufacturing Organisation (CDMO) is undergoing a fundamental transformation.
What was once a transactional relationship — executing defined processes on behalf of pharmaceutical companies — is now evolving into a far more strategic partnership.
Today’s customers are no longer simply outsourcing manufacturing.
They are seeking innovation, guidance, and expertise.
They expect CDMOs to:
- Educate them on best-in-class manufacturing practices
- De-risk development and scale-up decisions
- Benchmark processes against global standards
- Deliver consistent, compliant outcomes across the product lifecycle
This shift is redefining how CDMOs operate — and creating a clear divide between those who execute, and those who lead.
The Traditional CDMO Model — And Why It No Longer Fits
Historically, the CDMO model was built around execution.
A pharmaceutical company would:
- Develop a formulation
- Define a process
- Transfer that process to a CDMO
The CDMO’s role was to:
- Follow the process
- Manufacture the product
- Deliver within agreed specifications
While effective in simpler manufacturing environments, this model is increasingly misaligned with modern pharmaceutical demands.
The Shift: Customers Are Demanding More
Across the industry, a clear expectation is emerging:
CDMOs are no longer seen as service providers — they are expected to be strategic partners.
This means customers now expect CDMOs to:
- Challenge and improve process design
- Provide insight based on cross-industry experience
- Introduce innovative manufacturing approaches
- Benchmark processes against world-class standards
The expectation is not just delivery.
It is value creation.
The Rise of the Consultative CDMO
The most successful CDMOs are those embracing a consultative model.
This means moving beyond execution into:
Process Education
Helping customers understand:
- Why a process works
- Where risks exist
- How to optimise for scale and consistency
Benchmarking Against Best Practice
Bringing insight from:
- Multiple customers
- Different molecule types
- Global manufacturing environments
And using that to answer:
Is this the best way to do it — or just the way it’s always been done?”
Proactive Risk Mitigation
Identifying challenges before they occur:
- Scale-up inconsistency
- Blend uniformity failures
- Segregation risks
- Data integrity gaps
Innovation in Manufacturing Strategy
Recommending:
- Improved equipment selection
- Better process design
- Digitally enabled control systems
- More robust validation pathways
Powder Blending: A Critical Benchmark of CDMO Capability
Powder blending is one of the most telling indicators of whether a CDMO is operating at a world-class level.
It directly impacts:
- Content uniformity
- Product quality
- Batch repeatability
- Regulatory compliance
Yet it is often underestimated.
Common Challenges in Powder Blending
- Variability due to particle size and density differences
- Segregation during transfer and discharge
- Over-mixing leading to de-blending
- Poor scale-up from R&D to production
- Lack of real-time process visibility
What Customers Now Expect
Customers expect CDMOs to:
- Select the right blending technology for the formulation
- Design processes that scale predictably
- Ensure repeatable, validated outcomes
- Provide data that stands up under audit
In short:
Blending is no longer an operational step — it is a strategic capability.
Industry Perspective
From the front line of CDMO–supplier collaboration, this shift is becoming increasingly visible.
As Andy Brookes, Sales & Marketing Manager at Terriva, explains:
As Terriva has several CDMO customers who have purchased powder blending systems, it is becoming more common that our CDMO customers are telling us that their customers are demanding more than just a process, leaving the door open for industry leading CDMOs to take advantage of this desire for strategic partnership
This insight reflects a broader industry trend:
Demand is shifting toward CDMOs who can lead — not just deliver.
Enabling the Consultative CDMO: The Role of Engineering Partners
To meet these expectations, CDMOs must invest in:
- The right equipment
- The right control systems
- The right process expertise
This is where engineering partners play a critical role.
How Terriva Supports CDMOs Globally
At Terriva, we work with CDMOs across more than 50 countries, supporting them in elevating their powder handling and blending capabilities.
Our approach is built around enabling CDMOs to:
Benchmark Against World-Class Standards
- Proven blending technologies used globally
- Cross-industry insight into best practice
Design for Repeatability and Scale
- Consistent performance from R&D to production
- Reduced risk in validation and tech transfer
Strengthen Compliance and Data Integrity
- 21 CFR Part 11-ready control systems
- Audit-ready process data and traceability
Improve Process Understanding
- Support in identifying risks such as segregation and over-mixing
- Guidance on fill volumes, geometry, and process parameters
Deliver Flexible, Future-Proof Systems
- Adaptable to multiple products and batch sizes
- Designed for cleaning, containment, and changeover efficiency
The Competitive Advantage
The CDMOs that embrace this shift will gain a clear competitive advantage.
They will be able to:
- Win more complex, high-value projects
- Build stronger, longer-term customer relationships
- Reduce operational risk and rework
- Position themselves as leaders in manufacturing excellence
Conclusion
The question facing CDMOs is no longer:
Can we manufacture this product?
It is:
Can we guide our customers to a better, more robust, and more scalable way of manufacturing it?
The most valuable CDMOs are not those who follow processes —
but those who define them.
Frequently Asked Questions
A CDMO, or Contract Development and Manufacturing Organisation, supports pharmaceutical companies with drug development, scale-up and manufacturing. Modern CDMOs increasingly go beyond execution by offering strategic guidance, process optimisation and compliance expertise.
The role of the CDMO is evolving from a process executor to a strategic, consultative partner. Customers now expect CDMOs to provide innovation, benchmark best practices and deliver consistent, compliant manufacturing outcomes.
Pharmaceutical companies increasingly expect CDMOs to provide process expertise, reduce scale-up risk, support compliance, recommend best-in-class manufacturing approaches and deliver consistent, repeatable results.
Powder blending directly impacts content uniformity, product quality and batch consistency. Poor blending processes can lead to segregation, failed batches, validation delays and regulatory concerns.
CDMOs can improve powder blending performance by selecting the correct blending technology, optimising fill volumes and process parameters, reducing segregation risks during transfer, and implementing controlled, data-driven systems.
A consultative CDMO goes beyond manufacturing by educating customers, challenging process assumptions and recommending improved approaches based on industry experience, benchmarking and technical expertise.
21 CFR Part 11 requires electronic records and signatures to be secure, traceable and audit-ready. CDMOs must ensure their systems support data integrity and can demonstrate compliance under real-world audit conditions.
CDMOs can benchmark against world-class manufacturing by comparing their processes against global best practice, investing in modern compliant equipment, using data to validate consistency, and working with experienced engineering partners.
